Skip to main content
. 2015 Sep 25;10(9):e0139017. doi: 10.1371/journal.pone.0139017

Fig 2. Forest plot of comparison: 1) baseline drug resistance vs pansusceptible MTB, outcome of ADR: 1.2) ADR by region.

Fig 2

* 1 study was excluded as we were unable to obtain the exact proportion of patients in the study with non-MDR baseline drug resistance and baseline pan-susceptibility either from the paper or by contacting the authors. The endpoint used for the plot for 12 studies was acquisition of isoniazid/rifamycin/multidrug resistance [3,9,11,13,14,17,19,21,30,31,32,33] and the end point for 3 studies was acquisition of rifamycin resistance [8,28,35], based on data available.